Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials
Bio-Path Holdings, Inc. makes strides in RNA interference therapeutics, with its DNAbilize® platform showing potential in treating cancers, obesity, and type 2 diabetes, marking a significant step forward in biotechnology.
